文献速递肝肾功能剂量调整

慢性炎症疾病患者的小分子药物暴露高于健康志愿者:近期获批药物分析

Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs.
PubMed 文献 · Clin Pharmacol Ther · 2026-10-29

本文综述了FDA近15年批准用于重要慢性炎症适应症的小分子药物,基于已报道的群体药代动力学分析,20种药物中5种(25%)在患者中的AUC较健康志愿者高25%以上。这5种药物均主要经CYP3A4或CYP2C19代谢,其中4种代谢清除贡献超过50%。提示从健康志愿者向患者转化剂量预测时需评估慢性炎症对代谢活性的影响。

要点

  • 慢性炎症可下调CYP酶活性,导致患者药物暴露高于健康志愿者。
  • 20种小分子药物中5种(25%)在患者中AUC增加超过25%。
  • AUC升高的药物均经CYP3A4或CYP2C19代谢,多数代谢清除贡献>50%。

核心结论

  • 慢性炎症疾病患者中小分子药物暴露可能高于健康志愿者,需在剂量转化时考虑疾病-药物相互作用。

研究设计与样本

  • 综述分析FDA近15年批准用于慢性炎症适应症的小分子药物,基于已报道的群体药代动力学分析。

主要发现

  • 20种药物中5种(25%)在患者中AUC较健康志愿者高25%以上。
  • 5种药物均主要经CYP3A4或CYP2C19代谢,其中4种代谢清除贡献超过50%。

关键数值与推荐

  • AUC增加超过25%被视为有意义的暴露升高。
  • 5种药物均主要经CYP3A4或CYP2C19代谢。
  • 4种药物代谢对消除的贡献超过50%。

临床怎么用

  • 从健康志愿者向患者转化剂量预测时,应评估药物对慢性炎症下代谢活性变化的敏感性。
  • 关注经CYP3A4或CYP2C19代谢且代谢清除贡献高的药物,患者可能暴露更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic inflammation has long been known to downregulate the activity of certain cytochrome P450 (CYP) enzymes-the main enzymes responsible for the phase I metabolism of many small molecule drugs-potentially leading to higher exposures in patients with chronic inflammatory diseases compared to healthy volunteers. Neglecting this potential difference in the pharmacokinetics can have several implications for dose translation from healthy volunteers to proof of concept studies in patients: sub-optimal design of dose-ranging studies and increased risk of adverse events due to overprediction of safety margins. Yet this disease-drug interaction has rarely been prospectively considered in drug development in the past. This review aims to quantify the extent of decreased (apparent) clearance in patients compared to healthy volunteers of small molecule drugs that were approved by the FDA in the past 15 years for important chronic inflammatory indications. Based on reported population pharmacokinetic analyses, 25% (5 of 20) of small molecule drugs approved for the selected indications showed a meaningfully higher area under the curve (AUC) by more than 25% in patients compared to healthy volunteers. As a common feature, all five drugs are primarily metabolized by CYP3A4 or CYP2C19 and for four of the five drugs, the contribution of metabolism to their elimination is more than 50%. These findings highlight the need to assess a drug's susceptibility to changes in the metabolic activity under chronic inflammation when translating dose predictions from healthy volunteers to patients.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tillil J, Gopalakrishnan S, Dong J, et al. Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs. Clin Pharmacol Ther. 2026. PMID: 42957589. doi:10.1002/cpt.70535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。